98427-18-0

Usage

Uses

Used in Medicinal Chemistry:
5-cyclohexyl-1,3,4-oxadiazol-2-amine is used as a potential drug candidate for the treatment of various diseases due to its diverse biological activities and the possibility of being modified for specific therapeutic targets.
Used in Drug Design:
In the field of drug design, 5-cyclohexyl-1,3,4-oxadiazol-2-amine is utilized as a structural component in the development of new pharmaceuticals, leveraging its unique properties to enhance drug efficacy and selectivity.
Used in Pharmaceutical Industry:
5-cyclohexyl-1,3,4-oxadiazol-2-amine is used as a key intermediate in the synthesis of various pharmaceutical compounds, contributing to the advancement of novel therapeutic agents.
Used in Chemical Research:
5-cyclohexyl-1,3,4-oxadiazol-2-amine is also used in chemical research as a model for studying the properties and reactions of oxadiazole-containing molecules, which can lead to the discovery of new chemical entities with potential applications in various fields.
Used in Industrial Applications:
5-cyclohexyl-1,3,4-oxadiazol-2-amine's chemical properties make it a promising candidate for further studies and development in industrial applications, where its unique structure and reactivity could be harnessed for specific uses.

InChI:InChI=1/C8H13N3O/c9-8-11-10-7(12-8)6-4-2-1-3-5-6/h6H,1-5H2,(H2,9,11)

Upstream product

• 2043-61-0 cyclohexanecarbaldehyde 
• 506-68-3 bromocyane 
• 38941-47-8 cyclohexanecarbohydrazide 

Downstream Products

• 6694-52-6 1-(5-cyclohexyl-[1,3,4]oxadiazol-2-yl)-3-phenyl-[1,3]diazetidine-2,4-dione 
• 6694-40-2 1-(5-cyclohexyl-[1,3,4]oxadiazol-2-yl)-3-phenyl-urea 
• 6653-68-5 1-(5-cyclohexyl-[1,3,4]oxadiazol-2-yl)-3-phenyl-biuret 
• 6653-69-6 1-(5-cyclohexyl-[1,3,4]oxadiazol-2-yl)-5-methyl-3-phenyl-biuret 
• 6718-00-9 1-(5-cyclohexyl-[1,3,4]oxadiazol-2-yl)-5-ethyl-3-phenyl-biuret 
• 6694-08-2 5-(5-cyclohexyl-[1,3,4]oxadiazol-2-yl)-1,1-diethyl-3-phenyl-biuret 
• 6694-06-0 1-butyl-5-(5-cyclohexyl-[1,3,4]oxadiazol-2-yl)-3-phenyl-biuret 
• 6783-12-6 1-(5-cyclohexyl-[1,3,4]oxadiazol-2-yl)-5-(2-hydroxy-ethyl)-3-phenyl-biuret 
• 6718-02-1 4-(5-cyclohexyl-[1,3,4]oxadiazol-2-yl)-2-phenyl-allophanic acid pentyl ester 
• 6718-01-0 1-(5-cyclohexyl-[1,3,4]oxadiazol-2-yl)-3,5-diphenyl-biuret 
• 6694-07-1 1-cyclohexyl-5-(5-cyclohexyl-[1,3,4]oxadiazol-2-yl)-3-phenyl-biuret 

Relevant academic research and scientific papers

Optimization of a 1,3,4-oxadiazole series for inhibition of Ca2+/calmodulin-stimulated activity of adenylyl cyclases 1 and 8 for the treatment of chronic pain

Adenylyl cyclases type 1 (AC1) and 8 (AC8) are group 1 transmembrane adenylyl cyclases (AC) that are stimulated by Ca2+/calmodulin. Studies have shown that mice depleted of AC1 have attenuated inflammatory pain response, while AC1/AC8 double-knockout mice display both attenuated pain response and opioid dependence. Thus, AC1 has emerged as a promising new target for treating chronic pain and opioid abuse. We discovered that the 1,3,4-oxadiazole scaffold inhibits Ca2+/calmodulin-stimulated cyclic adenosine 3‘,5‘-monophosphate (cAMP) production in cells stably expressing either AC1 or AC8. We then carried out structure-activity relationship studies, in which we designed and synthesized 65 analogs, to modulate potency and selectivity versus each AC isoform in cells. Furthermore, molecular docking of the analogs into an AC1 homology model suggests the molecules may bind at the ATP binding site. Finally, a prioritized analog was tested in a mouse model of inflammatory pain and exhibited modest analgesic properties. In summary, our data indicate the 1,3,4-oxadiazoles represent a novel scaffold for the cellular inhibition of Ca2+/calmodulin-stimulated AC1- and AC8 cAMP and warrant further exploration as potential lead compounds for the treatment of chronic inflammatory pain.

ADENYLYL CYCLASE INHIBITORS FOR CHRONIC PAIN AND OPIOID DEPENDENCE

This present application disclosed a series of selective adenylyl cyclase 1 (AC1) inhibitors as a pain therapeutic. Those compounds may provide an effective method of treatment for chronic/inflammatory pain. Those compounds may also prevent opioid dependence and/or reduce opioid dependence. Both method and composition matters are within the scope of this invention.